The Lancet Regional Health – Southeast Asia
-
1
[Corrections] Retraction notice to “Economic burden of suicide deaths in India (2019): a retrospective, cross-sectional study” [The Lancet Regional Health – Southeast Asia 2024; (29): 100477]
-
2
[Viewpoint] Challenges in access to novel IgA nephropathy therapeutics in South Asia
-
3
[Articles] Incidence and mortality of invasive fungal infections among patients admitted in intensive care units in India: findings from a multicentric registry-based study (2023–25)
-
4
[Comment] India's indigenous CRISPR-based gene-editing therapy for sickle cell disease: innovation to equitable implementation
-
5
[Correspondence] South Asia's cardiometabolic burden: exposomal determinants of a health transition
-
6
[Articles] Effects of prenatal early food and micronutrient supplementations on body size and cardiometabolic risk factors in the 15-year-old offspring – the MINIMat randomised trial
-
7
[Comment] Accurately estimating unmet transplant need is essential for planning equitable transplantation services
-
8
[Correspondence] Bhotekoshi flash flood in Nepal: healthcare on the frontline
-
9
[Articles] Immunogenicity and safety of high-dose versus double-dose quadrivalent inactivated influenza vaccine in adult kidney transplant recipients: a randomized controlled trial (2023)
-
10
[Articles] Soil-transmitted helminthiasis prevalence and infection intensity among school-going children in Timor-Leste after the prolonged interruption of deworming: a cross-sectional survey (2025)
The Lancet Regional Health – Western Pacific
-
1
[Correspondence] Decentralised rare disease care for children living in remote areas: the Pilbara Hub Rare Care model in Western Australia
-
2
[Articles] Adult remaining life expectancy among Hong Kong-born and Mainland China/Macao/Taiwan-born residents in Hong Kong
-
3
[Viewpoint] Consensus and controversy of liquid biopsy using circulating tumour DNA (ctDNA) for molecular residual disease detection in colorectal cancer
-
4
[Articles] Postpartum risk and prognosis of pregnancy-associated intracerebral haemorrhage: a nationwide cohort-crossover study
-
5
[Articles] Spatiotemporal trajectories of antimicrobial resistance in bloodstream infections in China: a nationwide longitudinal surveillance study from 2014 to 2023
-
6
[Corrections] Corrigendum to “Effect of statins on the mortality of long-term survivors of nasopharyngeal carcinoma: population-based Study in endemic area” [The Lancet Regional Health–Western Pacific Volume 75 (2026) 101993]
-
7
[Review] Age-stratified health impacts of climate change on older adults in the Western Pacific Region: a scoping review
-
8
[Articles] A multidomain, nurse-led, mobile health-supported intervention for dementia risk reduction in primary care (HAPPI MIND): a pragmatic, single-blind, two-arm, cluster randomised controlled trial
-
9
[Articles] Implementation of the National Asthma Guidelines in New Zealand: a retrospective patient-level study of the change to anti-inflammatory reliever therapy in 324,972 patients
-
10
[Articles] The burden of bacterial antimicrobial resistance in the WHO Western Pacific Region 1990–2021: a cross-country systematic analysis with forecasts to 2050
The Lancet Respiratory Medicine
-
1
[Comment] Diagnostic labels, GETomics, and biostates in airway diseases
-
2
[Editorial] Preparedness for conflict in medical facilities
-
3
[News] European Respiratory Society International Congress 2026
-
4
[Spotlight] Medical oxygen supply in Zambia: beyond COVID-19
-
5
[Articles] Duration of effectiveness of tuberculosis preventive treatment across various tuberculosis burden settings: a systematic review and individual-participant meta-analysis
-
6
[Comment] Tuberculosis preventive treatment in high-burden settings: inequality in benefit, evidence, and potential harms
-
7
[Comment] Understanding US state-level heterogeneity in chronic respiratory disease burden
-
8
[Articles] State-level burden of chronic respiratory diseases in the USA, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023
-
9
[News] AI data centres could worsen US air pollution
-
10
[Corrections] Correction to Lancet Respir Med 2026; 14: 972–82
The Lancet Rheumatology
-
1
[Correspondence] Colitis in a patient with SLE treated with CAR T cells: LICATS or not?
-
2
[Correspondence] Low TRIM21 signal in Sjögren's: biomarker or analytical interference?
-
3
[Correspondence] Low TRIM21 signal in Sjögren's: biomarker or analytical interference? – Authors' reply
-
4
[Review] Innovative therapies in rheumatoid arthritis: CAR T cells and bispecific antibodies
-
5
[Editorial] CAR T cells in autoimmunity: safety first
-
6
[News] Research in Brief
-
7
[Review] CAR T cells for autoimmune diseases: 2026 update of the EBMT–ISCT–JACIE practice harmonisation and consensus recommendations
-
8
[Comment] Restoring immune tolerance in rheumatoid arthritis through PD-1 agonism
-
9
[Articles] Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial
-
10
[Comment] Predicting cytokine release syndrome after CAR T-cell therapy for autoimmune diseases
eClinicalMedicine
-
1
[Articles] Drug coated balloons versus drug eluting stents for de novo coronary artery disease: a systematic review and meta-analysis of randomised controlled trials
-
2
[Viewpoint] Promoting equitable cancer care: learnings from the development of the Optimal Care Pathway for people living in rural and remote areas with cancer
-
3
[Articles] Sex and disease differences in patients’ diagnostic experiences in autoimmune diseases: an international cross-sectional study
-
4
[News] EUSEM Congress 2026
-
5
[Articles] Dose-dependent efficacy and renal safety of pemafibrate versus fenofibrate in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia: a multicenter randomized controlled, open label trail
-
6
[Articles] The lancet commission definition of clinical obesity: a multi-cohort cross-sectional analysis from early childhood to older age in seven high-income countries
-
7
[Articles] Associations of digital media use with health, behavioural and developmental outcomes in children and adolescents: an umbrella review and meta-analysis
-
8
[Articles] Overnight metyrapone in mild autonomous cortisol secretion: a single-centre, single-arm, phase 2 trial
-
9
[Viewpoint] The clinical consequences of excessive caution: rethinking how cancer screening policy is made
-
10
[Articles] Outcome at ten years of children born preterm: the EPIPAGE-2 and ELFE cohort studies
The Lancet
-
1
[Comment] Faster troponin, same time in the emergency department: what is next for acute coronary syndrome assessment?
-
2
[Articles] Performance of 0/1 h versus 0/3 h pathways in patients with suspected myocardial infarction: a systematic review and individual participant data meta-analysis of randomised controlled trials
-
3
[Review] Irritable bowel syndrome and related disorders of gut–brain interaction
-
4
[Editorial] Health and poverty: lessons from China
-
5
[Comment] Beyond poverty eradication: what China's health and poverty alleviation experience means for global health
-
6
[The Lancet Commissions] A Lancet Commission on the Health and Poverty Alleviation Initiative in China
-
7
[Comment] Multiple standards of care in non-small-cell lung cancer after EGFR-TKI therapy: progress, fragmentation, or inevitability?
-
8
[Articles] Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China
-
9
[Articles] Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial
-
10
[Articles] Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-la
The Lancet Child & Adolescent Health
-
1
[Articles] Videolaryngoscopy versus direct laryngoscopy for nasotracheal intubation in infants undergoing cardiac procedures (NasoVISI): a multicentre, randomised controlled trial
-
2
[Reflections] Sonia Livingstone: getting children's digital rights right
-
3
[Comment] Mental health, ADHD, and autism: two reports, one call to act
-
4
[Comment] Paediatric liver transplantation: the risk of hepatic artery thrombosis
-
5
[Articles] Outcomes of hepatic artery thrombosis after paediatric liver transplantation (HEPATIC): an international, multicentre, retrospective registry study
-
6
[Reflections] Centring children and adolescents in drug policy development
-
7
[Comment] Growing up with congenital Zika syndrome
-
8
[Articles] Growth patterns of children with congenital Zika syndrome in Brazil: a matched-cohort study
-
9
[Articles] Safety, antiviral activity, and pharmacokinetics of long-acting cabotegravir plus long-acting rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): week 96 and end-of-study results from a multinational, pha
-
10
[Review] Mental health and urinary incontinence in childhood
The Lancet Diabetes & Endocrinology
-
1
[Correspondence] Iodine in the UK: the end of an “accidental public health triumph”
-
2
[Personal View] The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO
-
3
[Corrections] Correction to Lancet Diabetes Endocrinol 2026; 14: 894–902
-
4
[Correspondence] Multidisciplinary care of pituitary adenomas
-
5
[Review] Hashimoto's thyroiditis: two decades on
-
6
[Articles] Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial
-
7
[Comment] IL-2 and immunoregulatory therapies in newly diagnosed type 1 diabetes
-
8
[Comment] What Mauritius teaches us about diabetes surveillance
-
9
[Articles] Trends in prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a repeated cross-sectional study
-
10
[Editorial] Safeguarding paediatric metabolic health
The Lancet Gastroenterology & Hepatology
-
1
[Editorial] Guinea-Bissau HepB birth-dose vaccine trial: still unethical
-
2
[Review] Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the International Organization for the Study of IBD
-
3
[Comment] THR-β agonism in MASH: expanding the evidence to Asia
-
4
[Articles] Thyroid hormone receptor-β agonist simedeutirom (HSK31679) for Chinese patients with metabolic dysfunction-associated steatohepatitis: a 52-week, multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
-
5
[Review] Strategies to develop therapeutic cancer vaccines for pancreatic cancer
-
6
[Articles] Short-course prophylaxis with the Toronto HCV protocol for recipients of non-liver solid organ transplants from donors with hepatitis C viraemia: a retrospective, matched cohort study
-
7
[Review] Pain management in chronic pancreatitis: beyond opioids
-
8
[Articles] Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial
-
9
[Comment] Lessons from the European LiverScreen and Chinese LiverHealth projects
-
10
[Articles] Prevalence of liver fibrosis and steatotic liver disease in community-dwelling adults in China (the CHESS-LiverHealth project): cross-sectional baseline data from a prospective cohort study